TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
林水龍LIN, SHUEI-LIONG
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
32筆
1
Chang FC, Liu CH, Luo AJ, Tao-Min Huang T, Tsai MH, Chen YJ, Lai CF, Chiang CK, Lin TH, Chiang WC, Chen YM, Chu TS, Lin SL. Angiopoietin-2 inhibition attenuates kidney fibrosis by hindering chemokine C-C motif ligand 2 expression and apoptosis of endothelial cells. Kidney Int. 2022 Oct;102(4):780-797. doi: 10.1016/j.kint.2022.06.026. Epub 2022 Aug 4. PMID: 35934136.
2
Hung CT, Su TH, Chen YT, Wu YF, Chen YT, Lin SJ, Lin SL, Yang KC. Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFβ signalling. Gut. 2022 Sep;71(9):1876-1891. doi: 10.1136/gutjnl-2021-325065. Epub 2021 Dec 21. PMID: 34933915.
3
Cheng HT, Huang HC, Lee TY, Liao YH, Sheng YH, Jin PR, Huang KW, Chen LH, Chen YT, Liu ZY, Lin TC, Wang HC, Chao CH, Juang IP, Su CT, Huang KH, Lin SL, Wang J, Sung YC, Chen Y. Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis. J Control Release. 2022 Jun;346:169-179. doi: 10.1016/j.jconrel.2022.04.004. Epub 2022 Apr 23. PMID: 35429575.
4
Hung YH, Lai TS, Belmouaz M, Tu YC, Lai CF, Lin SL, Chen YM. Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Membranes (Basel). 2022 Apr 20;12(5):443. doi: 10.3390/membranes12050443. PMID: 35629769; PMCID: PMC9144787.
5
Wei YS, Cheng HP, Wu CH, Chang YC, Lin RW, Hsu YT, Chen YT, Lin SL, Tsai SY, Wu SC, Tsai PS. Oxidative Stress-Induced Alterations of Cellular Localization and Expression of Aquaporin 1 Lead to Defected Water Transport upon Peritoneal Fibrosis. Biomedicines. 2022 Mar 30;10(4):810. doi: 10.3390/biomedicines10040810. PMID: 35453560; PMCID: PMC9031283.
6
Hsu YH, Lin SL. Exploring the kidney disease data of Taiwan, a country with the highest incidence and prevalence of treated ESKD worldwide - Hints for public health and policy initiative. J Formos Med Assoc. 2022 Feb;121 Suppl 1:S1-S2. doi: 10.1016/j.jfma.2022.02.001. PMID: 35216767.
7
Chen YT, Lin SL. A Clinically Relevant Murine Model of Peritoneal Fibrosis by Dialysate and Catheters. J Vis Exp. 2022 Jun 10;(184). doi: 10.3791/63901. PMID: 35758703.
8
Shih HM, Pan SY, Wu CJ, Chou YH, Chen CY, Chang FC, Chen YT, Chiang WC, Tsai HC, Chen YM, Lin SL. Transforming growth factor-β1 decreases erythropoietin production through repressing hypoxia-inducible factor 2α in erythropoietin-producing cells. J Biomed Sci. 2021 Nov 2;28(1):73. doi: 10.1186/s12929-021-00770-2. PMID: 34724959; PMCID: PMC8561873.
9
Liao HW, Peng KY, Wu VC, Lin YH, Lin SL, Lin WC, Chueh JS, On Behalf Of Taipai Study Group. Characteristics of a Novel ATP2B3 K416_F418delinsN Mutation in a Classical Aldosterone-Producing Adenoma. Cancers (Basel). 2021 Sep 21;13(18):4729. doi: 10.3390/cancers13184729. PMID: 34572956; PMCID: PMC8472399.
10
Pan SY, Tsai PZ, Chou YH, Chang YT, Chang FC, Chiu YL, Chiang WC, Hsu T, Chen YM, Chu TS, Lin SL. Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis. Kidney Int. 2021 Jun;99(6):1354-1368. doi: 10.1016/j.kint.2021.01.017. Epub 2021 Mar 31. PMID: 33812664.
